Q3 2020 EPS Estimates for Catalent Inc Cut by Analyst (CTLT)

Catalent Inc (NYSE:CTLT) – Analysts at Jefferies Financial Group lowered their Q3 2020 earnings estimates for shares of Catalent in a report released on Wednesday, May 8th. Jefferies Financial Group analyst D. Windley now forecasts that the company will post earnings per share of $0.42 for the quarter, down from their prior forecast of $0.45. Jefferies Financial Group currently has a “Hold” rating and a $50.00 price objective on the stock.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.49 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.07. Catalent had a net margin of 6.01% and a return on equity of 16.78%. The firm had revenue of $617.50 million for the quarter, compared to analyst estimates of $644.88 million. During the same quarter in the previous year, the firm posted $0.41 earnings per share. The business’s revenue was down 1.7% on a year-over-year basis.

A number of other research firms also recently issued reports on CTLT. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a report on Wednesday, February 6th. Morgan Stanley lifted their price objective on shares of Catalent from $46.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, April 16th. ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. First Analysis reiterated an “outperform” rating and issued a $49.00 price objective on shares of Catalent in a report on Tuesday, March 5th. Finally, TheStreet upgraded shares of Catalent from a “c” rating to a “b-” rating in a report on Wednesday, February 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $49.57.

Shares of CTLT opened at $44.77 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.63 and a current ratio of 2.18. Catalent has a twelve month low of $29.23 and a twelve month high of $47.04. The company has a market capitalization of $6.52 billion, a price-to-earnings ratio of 28.16, a P/E/G ratio of 2.38 and a beta of 1.70.

In other news, SVP Lance Miyamoto sold 43,619 shares of Catalent stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $42.49, for a total value of $1,853,371.31. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP William Downie sold 7,315 shares of Catalent stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $42.00, for a total transaction of $307,230.00. The disclosure for this sale can be found here. Insiders sold 54,326 shares of company stock worth $2,303,676 over the last quarter. 1.40% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of CTLT. Rockefeller Capital Management L.P. acquired a new position in Catalent during the first quarter worth $31,000. Sageworth Trust Co acquired a new position in Catalent during the first quarter worth $32,000. Quantamental Technologies LLC acquired a new position in Catalent during the fourth quarter worth $47,000. Financial Gravity Wealth Inc. acquired a new position in Catalent during the first quarter worth $47,000. Finally, Bremer Bank National Association acquired a new position in Catalent during the first quarter worth $49,000. Institutional investors and hedge funds own 96.85% of the company’s stock.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Recommended Story: What is Cost of Capital?

Earnings History and Estimates for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.